MORVEN EDWARDS to Streptococcus agalactiae
This is a "connection" page, showing publications MORVEN EDWARDS has written about Streptococcus agalactiae.
Connection Strength
4.510
-
Immune Responses to Invasive Group B Streptococcal Disease in Adults. Emerg Infect Dis. 2016 11; 22(11):1877-1883.
Score: 0.491
-
Relevance of age at diagnosis to prevention of late-onset group B streptococcal disease by maternal immunization. Pediatr Infect Dis J. 2015 May; 34(5):538-9.
Score: 0.442
-
Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine. 2012 Jun 13; 30(28):4123-6.
Score: 0.359
-
Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J. 2010 Nov; 29(11):1009-12.
Score: 0.324
-
Group B streptococcal conjugate vaccine: a timely concept for which the time has come. Hum Vaccin. 2008 Nov-Dec; 4(6):444-8.
Score: 0.283
-
Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 2007 Jan 02; 25(1):55-63.
Score: 0.241
-
Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005 Sep 15; 41(6):839-47.
Score: 0.226
-
Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis. 2005 Feb 01; 40(3):352-7.
Score: 0.216
-
Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc. 2004 Jan; 52(1):46-50.
Score: 0.202
-
Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003 Jul 01; 188(1):66-73.
Score: 0.194
-
Group B Streptococcal Cellulitis-Adenitis Syndrome in Infants: Insights From 24 Years of Experience. J Pediatric Infect Dis Soc. 2022 Aug 30; 11(8):375-378.
Score: 0.184
-
Group B Streptococcal Disease: Interim Prevention at 50 Years and Counting. Clin Infect Dis. 2020 06 10; 70(12):2580-2581.
Score: 0.157
-
Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019 05; 19(5):e162-e171.
Score: 0.143
-
Prevalence and Capsular Types of Group B Streptococci Colonizing Indian Women Living in the United States. Pediatr Infect Dis J. 2018 06; 37(6):e175-e177.
Score: 0.137
-
Group B Streptococcal Colonization Among Pregnant Women in Delhi, India. Pediatr Infect Dis J. 2017 07; 36(7):665-669.
Score: 0.128
-
Serotype IV Streptococcus agalactiae ST-452 has arisen from large genomic recombination events between CC23 and the hypervirulent CC17 lineages. Sci Rep. 2016 07 14; 6:29799.
Score: 0.120
-
Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination. Vaccine. 2013 Aug 28; 31 Suppl 4:D66-71.
Score: 0.093
-
Long-term outcomes of group B streptococcal meningitis. Pediatrics. 2012 Jul; 130(1):e8-15.
Score: 0.090
-
Variation in reported neonatal group B streptococcal disease incidence in developing countries. Clin Infect Dis. 2012 Jul; 55(1):91-102.
Score: 0.090
-
Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease. Vaccine. 2008 Jan 24; 26(4):502-8.
Score: 0.066
-
Group B Streptococcus bacteremia elicits beta C protein-specific IgMand IgG in humans. J Infect Dis. 2007 Feb 01; 195(3):353-6.
Score: 0.062
-
Antibodies to type III group B streptococcal polysaccharide in breast milk. Pediatr Infect Dis J. 2004 Oct; 23(10):961-3.
Score: 0.053
-
Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis. 2004 Aug 01; 190(3):558-64.
Score: 0.052
-
Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004 Mar 15; 189(6):1103-12.
Score: 0.051
-
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun. 2002 Apr; 70(4):1724-38.
Score: 0.045
-
A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III. Clin Infect Dis. 2019 05 30; 68(12):2079-2086.
Score: 0.037
-
Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective? Vaccine. 2014 Aug 20; 32(37):4778-85.
Score: 0.026